Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956006 | 0.92 | GAA (0.45) | ACHEBCHEGAAALDH1A1LMNA | |
| SCHEMBL29954673 | 0.87 | GAA (0.38) | ACHEBCHEKMT2AGAAPAX8 | |
| SCHEMBL15214323 | 0.86 | ACHE (0.41) | ACHEBCHEKMT2AGAAPAX8 | |
| SCHEMBL29956135 | 0.84 | UTS2R (0.43) | ACHEBCHEKMT2AGAAMEN1 | |
| SCHEMBL4802706 | 0.84 | RAPGEF4 (0.39) | ACHEBCHEKMT2AGAAMEN1 | |
| SCHEMBL4799859 | 0.84 | ALDH1A1 (0.42) | ACHEBCHEKMT2AGAAMEN1 | |
| SCHEMBL408195 | 0.83 | NPY2R (0.47) | ACHEBCHEKMT2AGAAMEN1 | |
| SCHEMBL29952320 | 0.83 | ALDH1A1 (0.46) | ACHEBCHEKMT2AGAAMEN1 | |
| SCHEMBL5852069 | 0.83 | PTGS2 (0.41) | KMT2AGAAMEN1TP53ALDH1A1 | |
| SCHEMBL29955568 | 0.83 | PTGS2 (0.41) | KMT2AGAAMEN1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020188122-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2002-12-12 | — | — | US | claimed |
| EP-1227092-A2 | Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | claimed |
| CN-119954770-A | Imidazole compound and application thereof | 四川大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-113272298-B | Compounds and compositions for the treatment of respiratory diseases | 天莅生物技术有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-117747942-A | Electrolyte for improving normal temperature cycle performance and lithium ion battery | 合肥国轩高科动力能源有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4298094-A1 | ANALOGS FOR THE TREATMENT OF DISEASE | Insilico Medicine IP Limited (HK) | 2024-01-03 | — | — | EP | disclosed |
| CN-111936496-B | Heterocyclic compounds useful as medicaments | 马萨里克大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-117222642-A | Analogues for the treatment of disease | 英矽智能科技知识产权有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11498920-B2 | 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors | MASARYKOVA UNIVERZITA (CZ) | 2022-11-15 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022179529-A1 | ANALOGS FOR THE TREATMENT OF DISEASE | INSILICO MEDICINE IP LIMITED (CN) | 2022-09-01 | — | — | WO | disclosed |
| EP-0809499-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1997023479-A1 | NOVEL SYNTHESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498920-B2 | 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors | MALT1, BCL3, MCL1 | ACHE 4870/4885BCHE 4848/4885KMT2A 305/4885 |
| US-20020188122-A1 | Novel compounds | IL2, IFNG, IL1RN | ACHE 4842/4885BCHE 4465/4885KMT2A 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.